Back to News
Market Impact: 0.25
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
The Law Offices of Howard G. Smith announced an opportunity for investors with substantial losses in Capricor Therapeutics to lead a securities-fraud class action lawsuit. The notice signals litigation risk for the biotech company, though the excerpt provides no allegations, claimed damages, class period, or operational impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
CAPR-0.85
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Wells Fargo raises Regeneron stock price target to $925 on execution
- Deutsche Bank downgrades Novartis stock rating to sell on valuation
- United Therapeutics’ Rothblatt sells $4.7 million in stock
- Apple, Marriott International and 3 Stocks to Watch Heading Into Monday